D P Lindholm

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. doi request reprint Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors
    D P Lindholm
    Department of Endocrine Oncology, Uppsala University Hospital, Sweden
    Horm Metab Res 43:832-7. 2011
  2. doi request reprint Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma
    Daniel P Lindholm
    Department of Endocrine Oncology, Uppsala University Hospital, 75185 Uppsala, Sweden
    Med Oncol 29:301-3. 2012

Collaborators

Detail Information

Publications2

  1. doi request reprint Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors
    D P Lindholm
    Department of Endocrine Oncology, Uppsala University Hospital, Sweden
    Horm Metab Res 43:832-7. 2011
    ..Circulating tumor cells (CTC) have been applied in GEP-NETs quite recently. There is still an unmet need for new markers...
  2. doi request reprint Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma
    Daniel P Lindholm
    Department of Endocrine Oncology, Uppsala University Hospital, 75185 Uppsala, Sweden
    Med Oncol 29:301-3. 2012
    ..Temozolomide combined with bevacizumab might be a good treatment option in PDEC, perhaps even in a first-line setting. Prospective studies to answer this are warranted...